A few prescriptions can shift an employer’s pharmacy budget fast. For C-suite, HR, and finance leaders, that pressure is no longer only a pharmacy issue. It affects treatment access, employee trust, and the total cost of care.
TL;DR: Employers do not have to choose between access and cost control. A better approach combines education on generics and biosimilars, help with patient assistance programs, clear communication, and strong advocacy. A commonly repeated claim that 40% of employers supported patient assistance in 2025 could not be verified in current public data, but assistance programs are still a common affordability strategy.
Key Takeaways
- High-cost medications now influence plan spend, absenteeism, Adherence, and retention.
- Generics and biosimilars can lower cost without lowering clinical value when employees understand them.
- Patient assistance support matters when no lower-cost option exists or out-of-pocket costs stay high.
- Clear communication and advocacy turn confusing pharmacy rules into practical help.
Why high-cost medications are now a business issue, not just a pharmacy issue
High-cost drugs often improve care. They can help manage cancer, autoimmune disease, rare conditions, and complex chronic illness. At the same time, current employer projections show specialty drugs may account for more than 60% of pharmacy spend in 2026, even though they make up a small share of total prescriptions.
That kind of spending reaches far beyond HR. Finance sees budget volatility. Operations feels it through missed work and lower productivity. Leaders also see culture risks when employees feel abandoned during a serious health need. For added context, JA has shared more on specialty drug spending trends and how these costs shape employer plans.
What counts as a high-cost medication, and why these drugs drive so much spend
In plain language, a high-cost medication is any drug with a steep monthly or annual price tag. That group often includes specialty drugs, biologics, gene therapies, and other treatments that need special handling or close monitoring.
These drugs drive spend for two main reasons. First, the unit cost is high. Second, use is growing as new therapies reach market. Cancer treatments, immune therapies, and GLP-1 drugs have pushed trend higher. As a result, one or two members can account for a large share of pharmacy cost in a single year.
The hidden cost of confusion for employees and families
Price is only part of the problem. Confusion adds cost too.
When employees do not understand Formulary rules, prior authorization, Coinsurance, or lower-cost options, many delay treatment or skip refills. Studies on medication Adherence have long shown that workers who stay on needed treatment miss fewer workdays and use fewer disability days. On the other hand, surprise pharmacy costs often push people in the wrong direction.
That human side matters. A parent picking up a cancer drug or an employee starting therapy for Crohn’s disease does not need a maze. They need clear choices, timely answers, and a sense that their employer has their back.
Start with education on generics and biosimilars to lower cost without lowering quality
Education is often the fastest place to improve access and lower spend. Many employees still assume that a lower-cost drug must be weaker. That belief can block good decisions.
FDA-approved generic drugs are equivalent to brand drugs in dosage form, safety, strength, route of administration, quality, and intended use. Biosimilars are different because biologics are more complex, but the FDA says a biosimilar is highly similar to its reference product and has no clinically meaningful differences in safety or effectiveness.
This quick comparison helps frame the difference:
| Option | What it means | FDA standard | Cost effect |
|---|---|---|---|
| Generic | Copy of a brand small-molecule drug | Equivalent in key clinical measures | Often far lower than brand |
| Biosimilar | Highly similar version of a biologic | No clinically meaningful difference in safety or effectiveness | Can lower specialty spend meaningfully |
Savings can be substantial. Generics already carry much of the nation’s prescription volume, and biosimilars can cut costs by 25% to 85% in some settings. Yet adoption depends on trust, not only pricing.
How to explain generics in a way employees will trust
Most employees do not need a pharmacy lecture. They need a plain answer to a simple fear: “Will this work the same way?”
Start there. Use short FAQs, common examples, and pharmacist-backed language. Explain that generics meet the same FDA standards for quality and intended use. Also explain the member benefit in clear terms, lower out-of-pocket cost, lower plan spend, and often easier long-Term Adherence.
Short education pieces work better than dense guides. A one-page comparison, Open Enrollment webinar, and a dedicated help line can carry more weight than a long Formulary notice. Broader plan changes also matter, especially as newer rules increase focus on PBM transparency and prescription savings.
What employees need to know about biosimilars before they say no
Biosimilars create more hesitation because the word itself sounds unfamiliar. Employees may hear “similar” and assume “lesser.” That is where clear language matters.
A generic is a copy of a simpler drug. A biosimilar is a highly similar version of a complex biologic. It reaches the same clinical effect without meaningful loss in safety or efficacy. That point needs to come from trusted voices, including providers, pharmacists, and advocacy teams.
Rollout also matters. If a plan changes preferred products with little notice, resistance rises. If employees get advance notice, a plain explanation, and one-on-one support, acceptance improves. The goal is not only a lower claim cost. The goal is informed use of a sound clinical option.
Patient assistance programs can fill affordability gaps when drug costs stay high
Some drugs do not have a generic or biosimilar alternative. Others still create major out-of-pocket exposure, even when the plan covers them. That is where patient assistance programs, Copay cards, foundation support, and manufacturer programs can help.
These options are not a stand-alone answer. They work best as one part of a broader medication access strategy. They can bridge a gap, reduce immediate stress, and help employees start treatment on time. Public market discussions often point to employer interest in helping members find these programs, even though the specific 2025 claim of 40% support was not confirmed in current public reporting.
When patient assistance makes the biggest difference
Timing often decides whether help works. Employees need support quickly after a diagnosis, a new treatment order, or a coverage change. Delays can mean missed starts, worse symptoms, and higher medical spend later.
Assistance makes the biggest difference when a member faces high Deductible exposure, Coinsurance on a Specialty Drug, or a temporary gap during prior authorization or carrier transition. In those moments, even a short-Term bridge can keep treatment moving.
JA has also shared practical ideas on patient assistance for brand-name meds and other ways employees may reduce pharmacy cost.
Why navigation support matters more than simply listing resources
Most employees will not chase down five websites, compare eligibility rules, and gather paperwork while managing a serious condition. Even strong benefits can fail when the process feels hard.
That is why navigation matters. A guided conversation, document support, and follow-up can turn a confusing option into real access. This is where advocacy creates meaningful impact. Information alone rarely changes behavior. Support does.
Transparent communication and advocacy help employees use the right support at the right time
Pharmacy strategies break down when communication is late, vague, or filled with jargon. People accept change more readily when they know what is changing, why it is changing, and where to get help.
Clear medication communication protects trust. It also improves follow-through.
What clear medication communication should include
Good communication uses plain language and arrives early. It explains costs, coverage rules, alternatives, and next steps without sounding punitive. Employees should know who to call, what documents they may need, and how soon they should act.
Channel mix matters too. Email alone is rarely enough. Benefits guides, short webinars, manager talking points, Open Enrollment education, and advocacy hotlines all help. Communication should also fit the condition. A message about an allergy medication should not read like a notice about oncology treatment.
How advocacy services reduce frustration and improve follow-through
Advocacy teams can help members with prior authorizations, appeals, Specialty Pharmacy coordination, and lower-cost therapeutic options. They can also help locate assistance programs and explain what the PBM or carrier is asking for.
That support has financial value, but it also has emotional value. When an employee is sick, every phone transfer feels heavier. A strong advocate cuts through that friction. For employers, better follow-through means the plan works closer to the way it was designed to work.
A smarter employer strategy balances cost, trust, and long-Term outcomes
The strongest approach is balanced. It combines Plan Design, data review, member education, assistance navigation, and ongoing reporting. That kind of work supports leadership goals while also helping employees stay on needed treatment.
Leaders should track a small set of practical measures. Generic dispensing rate, biosimilar adoption where appropriate, specialty trend, Adherence indicators, employee questions, and member satisfaction all tell part of the story. Those are measurable outcomes, not guesswork.
The bigger point is simple. Success is not only a lower pharmacy line. Success is an employee who understands their options, gets needed medication on time, and feels supported through the process. That is better cost control, stronger culture, and stronger ROR, all at once.
High-cost medications will keep testing employer plans. Still, access and affordability can move in the same direction when leaders pair education with support.
A better medication strategy starts with clarity. When employees understand generics and biosimilars, get help finding assistance, and can reach a real advocate, costs become easier to manage and care becomes easier to use.
That is how employers move beyond short-Term savings and build a medication access strategy that works for the business and the people behind every claim.
